It's been a busy year for Bristol-Myers Squibb Co. The New York pharmaceuticals company sold its ConvaTec wound therapeutics unit to Nordic Capital and Avista Capital Partners for $4.1 billion in a transaction announced in May and closed in August; paid $253 million for Kosan Biosciences Inc. in June; and lost out to Eli Lilly and Co. in a bid for ImClone Systems Inc. If all goes as planned, Bristol-Myers will raise more than $500 million by selling shares in Mead Johnson Nutrition Co. Feb. 10, which would be the first U.S. initial public offering since Grand Canyon Education Inc. went public in November.
For legal advice, Bristol-Myers is using Susan Webster and Ronald Cami at Cravath, Swaine & Moore LLP, which advised on the three deals last year.Citigroup Inc. and Morgan Stanley are the lead underwriters on the IPO with Banc of America Securities LLC, Credit Suisse Group, J.P. Morgan Chase & Co., Lazard, RBC Capital Markets Corp. and UBS Investment Bank also on the syndicate. Richard D. Truesdell Jr. of Davis Polk & Wardwell represented the underwriters. Citi's Vikram Bhardwaj, Leon Kalvaria, Dave Magstadt, Christiana Stamoulis and Stephen Volk advised on both ConvaTec and ImClone, as did Morgan Stanley's Peter Crnkovich, Clinton Gartin and Todd Giardinelli. Credit Suisse's Martin Freeman, David Kostel, Stephanie Léouzon and Scott Lindsay chipped in on the ImClone bid, and Kostel represented Bristol-Myers on the Kosan acquisition.